We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients in India and internationally. Its principal products include Cilnidipine, Ranitidine, and Metronidazole. The company also provides contract manufacturing services for tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners. Further, the company provides its services in gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is based in Mumbai, India.
TODAY'S HIGH
2033.75
TODAY'S LOW
2010.55
52 WEEK HIGH
2150
52 WEEK LOW
1342.2
% of Shares Held by
All Insider
54.32%
% of Shares Held by
Institutions
23.52%
% of Float Held by
Institutions
51.49%
Number of Institutions
Holding Shares
62
MARKET CAP
15625.95 Cr.
ETERPRISE VALUE
15763.24 Cr.
NO. OF SHARES
7.73 Cr.
BOOK VALUE
299.385
DIV. YIELD
8%
DEBT
374.65 Cr.
GROSS PROFIT
1558.79 Cr.
CASH
196.81 Cr.
REVENUE
2819.49 Cr.
REVENUE/SHARE
364.814
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | 700.20 Cr. | -224.06 Cr. | 91.25 Cr. | 10.37 Cr. |
| Change To Liabilities | 52.83 Cr. | 46.47 Cr. | 52.10 Cr. | -28.57 Cr. |
| Total cashflows from Investing Activities | 2.31 Cr. | -230.67 Cr. | 23.92 Cr. | -27.66 Cr. |
| Net Borrowings | -8.36 Cr. | -7.83 Cr. | -2.36 Cr. | -5 Lakhs |
| Total Cash from Financing Activities | -138.38 Cr. | -87.42 Cr. | -306.05 Cr. | -155.73 Cr. |
| Other Liabilities | 0 | 0 | 0 | 21 Cr. |
| Total Assets | 0 | 0 | 0 | 0 |
| Net Income | 385.35 Cr. | 447.96 Cr. | 272.04 Cr. | 193.46 Cr. |
| Change in Cash | 34.07 Cr. | -3.27 Cr. | -6.38 Cr. | 10.89 Cr. |
| Effect of Exchange Rate | 10 k | 3.55 Lakhs | -1.29 Lakhs | -2.31 Lakhs |
| Total Cash from Operating Activities | 170.13 Cr. | 314.78 Cr. | 275.74 Cr. | 194.32 Cr. |
| Depreciation | 72.65 Cr. | 68.32 Cr. | 65.99 Cr. | 54.87 Cr. |
| Other Cashflows from Investing Activities | 1.12 Cr. | 1.27 Cr. | 3.17 Cr. | 3.75 Cr. |
| Dividends Paid | -127.56 Cr. | -73.24 Cr. | -141 Cr. | -20.79 Cr. |
| Change to Inventory | -62.51 Cr. | -70.08 Cr. | -30.91 Cr. | -30.02 Cr. |
| Change to Account Receivables | -292.83 Cr. | -70.59 Cr. | -11.49 Cr. | -13.87 Cr. |
| Other Cashflows from Financing Activities | -2.45 Cr. | -6.34 Cr. | -1.86 Cr. | -3.86 Cr. |
| Change to Net Income | 14.63 Cr. | -107.63 Cr. | -72.32 Cr. | -3.31 Cr. |
| Capital Expenditures | -62.87 Cr. | -47.77 Cr. | -72.96 Cr. | -49.12 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 504.90 Cr. | 596.88 Cr. | 348.89 Cr. | 286.99 Cr. |
| Minority Interest | 4.48 Cr. | 3.70 Cr. | 2.50 Cr. | 2.80 Cr. |
| Net Income | 470.79 Cr. | 487.31 Cr. | 318.21 Cr. | 258.25 Cr. |
| Selling General Administrative | 439.24 Cr. | 425.77 Cr. | 406.83 Cr. | 382.03 Cr. |
| Gross Profit | 1581.30 Cr. | 1319.80 Cr. | 1122.22 Cr. | 1023.93 Cr. |
| Ebit | 470.79 Cr. | 487.31 Cr. | 318.21 Cr. | 258.25 Cr. |
| Operating Income | 470.79 Cr. | 487.31 Cr. | 318.21 Cr. | 258.25 Cr. |
| Other Operating Expenses | 598.61 Cr. | 338.05 Cr. | 330.84 Cr. | 328.13 Cr. |
| Interest Expense | -5.12 Cr. | -6.74 Cr. | -2.91 Cr. | -3.41 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 118.86 Cr. | 148.36 Cr. | 76.50 Cr. | 93.02 Cr. |
| Total Revenue | 2424.24 Cr. | 2042.52 Cr. | 1774.72 Cr. | 1643.20 Cr. |
| Total Operating Expenses | 1953.44 Cr. | 1555.21 Cr. | 1456.51 Cr. | 1384.94 Cr. |
| Cost of Revenue | 842.93 Cr. | 722.71 Cr. | 652.50 Cr. | 619.26 Cr. |
| Total Other Income Expense Net | 34.10 Cr. | 109.57 Cr. | 30.67 Cr. | 28.73 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | 386.03 Cr. | 448.52 Cr. | 272.39 Cr. | 193.96 Cr. |
| Net Income Applicable to Common Shares | 385.35 Cr. | 447.96 Cr. | 272.04 Cr. | 193.46 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 671.39 Cr. | 32.10 Cr. | 30.09 Cr. | 23.37 Cr. |
| Capital Surplus | 0 | 50.76 Cr. | 50.76 Cr. | 50.76 Cr. |
| Total Liabilities | 468.78 Cr. | 424.68 Cr. | 382.57 Cr. | 309.02 Cr. |
| Stock Holder Equity | 2134.12 Cr. | 1809.72 Cr. | 1435.48 Cr. | 1480.12 Cr. |
| Minority Interest | 4.48 Cr. | 3.70 Cr. | 2.50 Cr. | 2.80 Cr. |
| Other Liabilities | 125.29 Cr. | 102.68 Cr. | 103.72 Cr. | 97.03 Cr. |
| Total Assets | 2607.40 Cr. | 2238.11 Cr. | 1820.56 Cr. | 1791.94 Cr. |
| Common Stock | 15.45 Cr. | 15.45 Cr. | 15.45 Cr. | 16.04 Cr. |
| Retained Earnings | 0 | 1735.41 Cr. | 1373.37 Cr. | 1413.87 Cr. |
| Other Liabilities | 64.45 Cr. | 74.27 Cr. | 68.07 Cr. | 64.83 Cr. |
| Good Will | 57.45 Cr. | 57.45 Cr. | 53.14 Cr. | 53.14 Cr. |
| Treasury Stock | 2118.66 Cr. | 8.08 Cr. | -4.10 Cr. | -56.98 Lakhs |
| Other Assets | 19.33 Cr. | 13.38 Cr. | 10.52 Cr. | 8.89 Cr. |
| Cash | 58.52 Cr. | 28.68 Cr. | 29 Cr. | 35.39 Cr. |
| Current Liabilities | 383.71 Cr. | 345.27 Cr. | 313.26 Cr. | 244.18 Cr. |
| Long Term Asset Charges | 6.43 Cr. | 6.94 Cr. | 6.57 Cr. | 0 |
| Short Long Term Debt | 0 | 0 | 0 | 0 |
| Other Stockholder Equity | 2118.66 Cr. | 8.08 Cr. | -4.10 Cr. | -56.98 Lakhs |
| Property Plant Equipment | 566.81 Cr. | 569.65 Cr. | 584.19 Cr. | 559.50 Cr. |
| Total Cur. Assets | 1274.85 Cr. | 1552.60 Cr. | 1073.15 Cr. | 1051.15 Cr. |
| Long Term Investments | 17.54 Cr. | 12.90 Cr. | 69.45 Cr. | 95.87 Cr. |
| Net Tangible Assets | 1405.26 Cr. | 1720.16 Cr. | 1352.25 Cr. | 1403.60 Cr. |
| Short Term Investments | 0 | 0 | 0 | 2.99 Cr. |
| Net Receivables | 556.99 Cr. | 399.24 Cr. | 361.35 Cr. | 324.83 Cr. |
| Long Term Debt | 0 | 0 | 0 | 0 |
| Inventory | 409.96 Cr. | 347.44 Cr. | 274.66 Cr. | 243.75 Cr. |
| Accounts Payable | 224.47 Cr. | 186.92 Cr. | 167.96 Cr. | 117.37 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account